Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Regulatory
Approvals worldwideDrug spendingDrug targets
Regulatory · NICE technology appraisal guidance · England

NICE technology appraisals

Every medicine and treatment NICE has appraised for the NHS in England since 2000: NICE's recommendation, when it was published, whether it still stands, and a link to the guidance and to the medicine's trials on this site.

Source: NICE technology appraisal guidance and NICE's appraisal recommendations data, shown with NICE's permission. Checked 3 Oct 2026
1,189Technology appraisals published
90%Of 897 current decided appraisals recommend for at least some patients
72Published in 2026 so far
976Linked to a medicine page here
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from NICE technology appraisal guidance · Last verified · Editorial standards

NICE has published 1,189 technology appraisals since 2000, and 1,062 of them are still current. Of the current appraisals where NICE reached a decision, 90% recommend the medicine or treatment for at least some patients, including through the Cancer Drugs Fund. The most recent is TA1189, published 26 Aug 2026. NICE's decisions apply to the NHS in England; in Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics.

01

What NICE decided

Appraisals by recommendation type
Recommended or optimised
836
Cancer Drugs Fund or Innovative Medicines Fund
64
Only in research
23
Not recommended
145
Terminated (no company submission)
177

An appraisal can contain several recommendations, for different groups of patients, so it can appear under more than one type. These explanations are ours; NICE's own definitions are on nice.org.uk.

02

Recommended or optimised

836 appraisals, newest first, page 5 of 9
AppraisalMedicine pageNICE recommendationPublishedStatus
Nusinersen for treating spinal muscular atrophy
NICE TA588
NusinersenOptimised24 Jul 2019Current
Lenalidomide plus dexamethasone for previously untreated multiple myeloma
NICE TA587
LenalidomideOptimised26 Jun 2019Current
Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib
NICE TA586
LenalidomideOptimised26 Jun 2019Current
Ocrelizumab for treating primary progressive multiple sclerosis
NICE TA585
OcrelizumabRecommended12 Jun 2019Current
Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
NICE TA584
—Recommended5 Jun 2019Current
Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes
NICE TA583
ErtugliflozinOptimised5 Jun 2019Current
Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
NICE TA577
Brentuximab VedotinOptimised24 Apr 2019Current
Tildrakizumab for treating moderate to severe plaque psoriasis
NICE TA575
—Recommended17 Apr 2019Current
Certolizumab pegol for treating moderate to severe plaque psoriasis
NICE TA574
Certolizumab PegolOptimised17 Apr 2019Current
Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes
NICE TA572
ErtugliflozinRecommended27 Mar 2019Current
Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
NICE TA571
BrigatinibRecommended20 Mar 2019Current
Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
NICE TA569
PertuzumabOptimised20 Mar 2019Current
Cochlear implants for children and adults with severe to profound deafness
NICE TA566
—Recommended Optimised Not recommended7 Mar 2019Current
Benralizumab for treating severe eosinophilic asthma
NICE TA565
BenralizumabOptimised6 Mar 2019
Updated 3 Sep 2019
Current
Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
NICE TA563
AbemaciclibRecommended27 Feb 2019Current
Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
NICE TA562
EncorafenibRecommended27 Feb 2019Current
Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
NICE TA561
VenetoclaxRecommended27 Feb 2019Current
Regorafenib for previously treated advanced hepatocellular carcinoma
NICE TA555
RegorafenibOptimised9 Jan 2019Current
Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia
NICE TA552
DaunorubicinRecommended19 Dec 2018Current
Lenvatinib for untreated advanced hepatocellular carcinoma
NICE TA551
LenvatinibOptimised19 Dec 2018Current
Tofacitinib for moderately to severely active ulcerative colitis
NICE TA547
TofacitinibRecommended28 Nov 2018Current
Gemtuzumab ozogamicin for untreated acute myeloid leukaemia
NICE TA545
Gemtuzumab OzogamicinOptimised14 Nov 2018Current
Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
NICE TA544
DabrafenibRecommended17 Oct 2018Current
Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
NICE TA543
TofacitinibRecommended3 Oct 2018Current
Cabozantinib for untreated advanced renal cell carcinoma
NICE TA542
CabozantinibRecommended3 Oct 2018Current
Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
NICE TA541
—Recommended19 Sep 2018Current
Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours
NICE TA539
—Recommended29 Aug 2018Current
Dinutuximab beta for treating neuroblastoma
NICE TA538
DinutuximabRecommended22 Aug 2018Current
Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
NICE TA537
IxekizumabRecommended8 Aug 2018Current
Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
NICE TA536
AlectinibRecommended8 Aug 2018Current
Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
NICE TA535
Lenvatinib, SorafenibOptimised8 Aug 2018Current
Dupilumab for treating moderate to severe atopic dermatitis
NICE TA534
DupilumabOptimised1 Aug 2018Current
Ocrelizumab for treating relapsing–remitting multiple sclerosis
NICE TA533
OcrelizumabOptimised25 Jul 2018Current
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
NICE TA531
PembrolizumabOptimised18 Jul 2018Current
Beta interferons and glatiramer acetate for treating multiple sclerosis
NICE TA527
—Recommended Not recommended27 Jun 2018Current
Arsenic trioxide for treating acute promyelocytic leukaemia
NICE TA526
Arsenic TrioxideRecommended13 Jun 2018Current
Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
NICE TA525
AtezolizumabRecommended13 Jun 2018Current
Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
NICE TA524
Brentuximab VedotinOptimised13 Jun 2018Current
Midostaurin for untreated acute myeloid leukaemia
NICE TA523
MidostaurinRecommended13 Jun 2018Current
Guselkumab for treating moderate to severe plaque psoriasis
NICE TA521
GuselkumabRecommended13 Jun 2018Current
Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
NICE TA520
AtezolizumabOptimised16 May 2018Current
Tocilizumab for treating giant cell arteritis
NICE TA518
—Optimised18 Apr 2018Current
Avelumab for treating metastatic Merkel cell carcinoma
NICE TA517
AvelumabRecommended Recommended (Cancer Drugs Fund)11 Apr 2018
Updated 21 Apr 2021
Current
Cabozantinib for treating medullary thyroid cancer
NICE TA516
CabozantinibRecommended28 Mar 2018Current
Obinutuzumab for untreated advanced follicular lymphoma
NICE TA513
ObinutuzumabRecommended21 Mar 2018Current
Tivozanib for treating advanced renal cell carcinoma
NICE TA512
TivozanibRecommended21 Mar 2018Current
Brodalumab for treating moderate to severe plaque psoriasis
NICE TA511
BrodalumabRecommended21 Mar 2018Current
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
NICE TA509
PertuzumabRecommended7 Mar 2018Current
Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee
NICE TA508
—Optimised7 Mar 2018Current
Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C
NICE TA507
—Optimised21 Feb 2018Current
Pirfenidone for treating idiopathic pulmonary fibrosis
NICE TA504
PirfenidoneOptimised6 Feb 2018Current
Ibrutinib for treating relapsed or refractory mantle cell lymphoma
NICE TA502
IbrutinibOptimised31 Jan 2018Current
Ceritinib for untreated ALK-positive non-small-cell lung cancer
NICE TA500
CeritinibRecommended24 Jan 2018Current
Glecaprevir–pibrentasvir for treating chronic hepatitis C
NICE TA499
—Recommended24 Jan 2018Current
Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
NICE TA498
LenvatinibRecommended24 Jan 2018Current
Golimumab for treating active non-radiographic axial spondyloarthritis
NICE TA497
GolimumabRecommended10 Jan 2018Current
Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
NICE TA496
RibociclibRecommended20 Dec 2017Current
Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
NICE TA495
PalbociclibRecommended20 Dec 2017Current
Cladribine tablets for treating relapsing–remitting multiple sclerosis
NICE TA493
CladribineOptimised6 Dec 2017Replaced by TA616
Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
NICE TA488
RegorafenibOptimised15 Nov 2017Current
Aflibercept for treating choroidal neovascularisation
NICE TA486
AfliberceptRecommended1 Nov 2017Current
Sarilumab for moderate to severe rheumatoid arthritis
NICE TA485
SarilumabOptimised1 Nov 2017Current
Immunosuppressive therapy for kidney transplant in children and young people
NICE TA482
Basiliximab, Mycophenolate Mofetil, Tacrolimus, Sirolimus, Everolimus, BelataceptRecommended Not recommended11 Oct 2017Current
Immunosuppressive therapy for kidney transplant in adults
NICE TA481
Basiliximab, Mycophenolate Mofetil, Tacrolimus, Sirolimus, Everolimus, BelataceptRecommended Not recommended11 Oct 2017Current
Tofacitinib for moderate to severe rheumatoid arthritis
NICE TA480
TofacitinibOptimised11 Oct 2017Current
Reslizumab for treating severe eosinophilic asthma
NICE TA479
—Optimised4 Oct 2017Current
Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
NICE TA478
Brentuximab VedotinOptimised4 Oct 2017Current
Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee
NICE TA477
—Optimised4 Oct 2017Current
Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
NICE TA476
—Optimised6 Sep 2017Current
Dimethyl fumarate for treating moderate to severe plaque psoriasis
NICE TA475
—Optimised6 Sep 2017Current
Sorafenib for treating advanced hepatocellular carcinoma
NICE TA474
SorafenibOptimised6 Sep 2017Current
Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
NICE TA473
CetuximabOptimised31 Aug 2017Current
Eluxadoline for treating irritable bowel syndrome with diarrhoea
NICE TA471
—Recommended30 Aug 2017Current
Holoclar for treating limbal stem cell deficiency after eye burns
NICE TA467
—Optimised Only in research16 Aug 2017Current
Baricitinib for moderate to severe rheumatoid arthritis
NICE TA466
BaricitinibOptimised9 Aug 2017Current
Bisphosphonates for treating osteoporosis
NICE TA464
BisphosphonatesOptimised9 Aug 2017
Updated 8 Jul 2019
Current
Cabozantinib for previously treated advanced renal cell carcinoma
NICE TA463
CabozantinibRecommended9 Aug 2017Current
Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
NICE TA462
NivolumabRecommended26 Jul 2017Current
Roflumilast for treating chronic obstructive pulmonary disease
NICE TA461
—Optimised26 Jul 2017Current
Adalimumab and dexamethasone for treating non-infectious uveitis
NICE TA460
Adalimumab, DexamethasoneOptimised26 Jul 2017Current
Collagenase clostridium histolyticum for treating Dupuytren's contracture
NICE TA459
—Optimised26 Jul 2017Current
Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
NICE TA458
Trastuzumab emtansineRecommended19 Jul 2017
Updated 20 Nov 2017
Current
Carfilzomib for previously treated multiple myeloma
NICE TA457
CarfilzomibOptimised19 Jul 2017Current
Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
NICE TA456
UstekinumabRecommended12 Jul 2017Current
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
NICE TA455
Adalimumab, Etanercept, UstekinumabOptimised12 Jul 2017Current
Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
NICE TA451
PonatinibRecommended28 Jun 2017Current
Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia
NICE TA450
BlinatumomabRecommended28 Jun 2017Current
Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
NICE TA449
Everolimus, SunitinibRecommended28 Jun 2017Current
Etelcalcetide for treating secondary hyperparathyroidism
NICE TA448
EtelcalcetideOptimised28 Jun 2017Current
Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
NICE TA446
Brentuximab VedotinOptimised Optimised (Cancer Drugs Fund)28 Jun 2017Current
Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
NICE TA445
—Optimised24 May 2017Current
Obeticholic acid for treating primary biliary cholangitis
NICE TA443
—Recommended26 Apr 2017Current
Ixekizumab for treating moderate to severe plaque psoriasis
NICE TA442
IxekizumabOptimised26 Apr 2017Current
Daclizumab for treating relapsing–remitting multiple sclerosis
NICE TA441
—Optimised26 Apr 2017Withdrawn
Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
NICE TA439
Cetuximab, PanitumumabRecommended29 Mar 2017
Updated 25 Sep 2017
Current
Apremilast for treating active psoriatic arthritis
NICE TA433
ApremilastOptimised22 Feb 2017Current
Everolimus for advanced renal cell carcinoma after previous treatment
NICE TA432
EverolimusRecommended22 Feb 2017Current
Mepolizumab for treating severe refractory eosinophilic asthma
NICE TA431
—Optimised25 Jan 2017Current
Sofosbuvir–velpatasvir for treating chronic hepatitis C
NICE TA430
—Optimised25 Jan 2017Current
Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
NICE TA429
—Recommended25 Jan 2017Current

Titles link to the guidance on nice.org.uk, where the full recommendations are. A medicine is linked to its page here only when the name NICE appraised is exactly the same molecule as ours; medicines given alongside it (“with chemotherapy”) are not counted as appraised. Appraisals of devices and procedures are listed but have no medicine page.

© NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Medicines data, weekly

One email every Friday: new approvals, trials and shortages, with every figure linked to its source.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

NICE has allowed us to show the appraisal number, title, recommendation category and dates of each technology appraisal, with a link to the guidance. No guidance text is reproduced.

A nightly job reads NICE's recommendations data, reads each new appraisal page once and re-checks every page every 60 days for replaced or withdrawn guidance. It keeps the previous version if a refresh fails. No AI drafting. See our methodology. The NICE data on this page was last retrieved on 3 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.